Sequenom: Wie weit führt der Ausbruch? - 500 Beiträge pro Seite

[S.Ochsenkühn]

Die Aktien der Biotechnologiefirma Sequenom (Nasdaq: SQNM) scheinen in den letzten beiden Wochen eine interessante Entwicklung zu zeigen. Nach einer langen Seitwärtsphase im August ist zum September der Ausbruch gelungen.

In den letzten beiden Wochen bewegt sich die Aktie in einem steilen Trendkanal (lila) nach oben. Ob dieser allerdings gehalten werden kann ist fraglich. Da Sequenom nach dem Ausbruch jedoch bereits einen Pull-Back gezeigt hat, ist es eher unwahrscheinlich, dass sich der Anteilsschein bei einem Bruch des Trendkanals nochmals zurück zu den Ausbruchsniveaus bei 30 Dollar begibt.



Bei weiterem Aufwärtsdrang stellt sich der Aktie bis in den Bereich 50-52 US-Dollar wenig in den Weg. Bei einem unerwarteten erneuten starken Pull-Back muss die Marke von 30 Dollar halten. Ansonsten wird sich Aktie wieder in der Seitwärtskonsolidierung ausbreiten und möglicherweise gar bis auf 25 Dollar nachgeben.

Die Markttechnik liefert ein gemischtes Bild. Der 21er-AMA steigt an und signalisiert einen Aufwärtstrend. Der Trendbestimmungsindikator Aroon pocht jedoch weiterhin auf einen Seitwärtsmarkt. Der MACD liegt knapp über seiner Triggerlinie, steht also auf „Kaufen“. Auf der anderen Seite sieht der ProjectionOscillator für die nächsten Tage schwächere Kurse. Aber es gibt noch ein sehr gutes Zeichen. Die Umsätze haben sich mit dem Aufwärtstrend stark erhöht (blau hinterlegt).



Markante Unterstützungen aus Fibonacci-Sicht liegen bei 35,7 und 33 Dollar. Dort verlaufen die Retracements (weiß) und Fanlines (rot) des kurzfristigen Szenarios. Die Time-Zone-Analyse sagt für heute einen Extrempunkt voraus.

Fazit: Nachdem der Wert im Juni schon einen Ausbruch versucht hat, der aber sehr früh wieder erstickt wurde, ist die Entwicklung dieses Ausbruchs spannend. Die Charttechnik sieht sehr gut aus, lediglich die Markttechnik sollte sich noch verbessern. Kurse von 50 Dollar scheinen aber möglich. Und danach könnte es erst richtig interessant werden, denn immerhin kommt die Aktie von 190 US-Dollar.

Die Analyse basiert auf den Kursen des Wertes an der Heimatbörse. Bei ausländischen Werten ist die Analyse auf die in Deutschland gehandelten Wertpapiere übertragbar, da sich die Wertentwicklung an dem Basiswert orientiert. Durch Währungsschwankungen sowie eine geringere Liquidität kann es jedoch zu Abweichungen kommen. Die Analyse wurde nach bestem Wissen und Gewissen erstellt, mögliche Fehler können aber nicht ausgeschlossen werden. Zudem wollen wir damit keine Kauf- oder Verkaufempfehlungen geben und äußern nur unsere subjektive Meinung zu der momentanen charttechnischen Situation einer Aktie. Auf keinen Fall sollte diese Beurteilung alleine für eine zu treffende Kauf- oder Verkaufentscheidung maßgeblich herangezogen werden.

[raimundK]

Hallo, Chartexperten!
Ich bin mir durchaus bewusst, dass der Chart einer Aktie viel Aussagekraft haben kann, auch im Hinblick auf die zukünftige Entwicklung. Ein Punkt wird aber m. E. oft außer Acht gelassen: Sobald besondere Umstände die "althergebrachte" Börsenmechanik und -psychologie verfälschen, ist die Charttechnik nutzlos.
So auch im Fall SEQUENOM. Hier ist durch die (erwarteten) Insiderverkäufe nach Ablauf der Lockup-Periode und die besondere Fixierung von Tradern und Shorties auf diese Aktie eine besonders unberechenbare Situation entstanden. Auch das Geschäftsfeld Genomik ist nicht unbedingt eine gute Voraussetzung für Chartanalysen. Hier spielen Faktoren eine Rolle, die sich einer nüchternen, technischen Analyse entziehen.
Ich glaube, wer sich bei SEQUENOM auf die Charttechnik verlässt, ist verlassen. Wundert Euch nicht, wenn morgen der Kurs auf Grund einer belanglosen Meldung explodiert oder ohne fundamentale Gründe einbricht, nur weil die Trader von der Kursentwicklung der letzten Tage enttäuscht sind.
Vielleicht ist SQNM aber gerade deshalb so spannend?

Ciao, R.

[siek]

@ all
System Purchase by Hitachi Marks SEQUENOM`s Entry Into Asian Market

SAN DIEGO, Sept. 29 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM), the
leading provider of single nucleotide polymorphism (SNP) analysis strategies
and technology, today announced that it has sold four additional MassARRAY
systems, raising SEQUENOM`s installed commercial base of systems to 16.
Hitachi, Ltd. (NYSE: HIT), a leading global electronics company, has
purchased a MassARRAY system following the company`s recent expansion into the
life science arena. Hitachi`s Life Science Group has chosen the MassARRAY
system for its internal SNP marker validation projects while providing
genotyping services to the Japanese SNP analysis market. Hitachi established
the Life Science Group last year to promote the growth of biotechnology
businesses in Japan and to improve the health and prosperity of people around
the world.
Genetics Institute, a unit of Wyeth-Ayerst and a wholly owned subsidiary
of American Home Products Corporation (NYSE: AHP), has purchased a MassARRAY
system for the high throughput quality control of oligonucleotides, short
strands of synthetic DNA used in various genomics research programs at
Genetics Institute and Wyeth-Ayerst. SEQUENOM`s MassARRAY system is the
recognized gold standard for oligonucleotide quality control.
Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC), a leader in applying
population genomics and informatics to the development of personalized
medicines, has purchased a second MassARRAY system for high-throughput SNP
analysis. The additional system purchase follows a previously announced
agreement between the two companies establishing SEQUENOM`s MassARRAY system
as the exclusive platform for Genaissance`s HAP Typing(TM) facility. The
facility was designed for the high-throughput analysis of samples from
clinical trials.
Integrated DNA Technologies, Inc. (IDT), a leader in high volume
oligonucleotide production, has also purchased a second MassARRAY system from
SEQUENOM. IDT has integrated the MassARRAY technology into its high
throughput oligonucleotide synthesis platform to support its automated
production and quality control. The previously announced agreement secures a
dedicated and reliable supply of oligonucleotides, a critical factor in assay
development and utilization of genotyping technologies, for SEQUENOM and its
customers.
"Hitachi, Genetics Institute, Genaissance and IDT represent four distinct
segments in genomics and we are pleased that they have each chosen our
MassARRAY system," said Toni Schuh, Ph.D., SEQUENOM`s President and CEO. "In
particular, we are pleased with the opportunity to participate in the emerging
Asian biotechnology market through our relationship with Hitachi. This marks
our entry into a market with largely untapped growth potential and symbolizes
the widespread demand for our technology.
"SEQUENOM`s technology and integrated approach to SNP analysis enable full
genome scans, which gives us a leadership position in the field," continued
Dr. Schuh. "Our unique competitive advantages include automated
high-throughput assay design, the ability to determine allele frequencies, the
availability of an in-house reference DNA bank and ultimate data quality.
SEQUENOM`s customers buy more than just genotyping technology; they buy a
relationship with our company. Our increasing number of customers
demonstrates confidence in this approach and supports our leadership
position."

About Hitachi, Ltd.
Hitachi, Ltd., headquartered in Tokyo, Japan, is one of the world`s
leading global electronics companies, with fiscal 1999 (ended March 31, 2000)
consolidated sales of 8,001 billion yen ($75.5 billion*). The company
manufactures and markets a wide range of products, including computers,
semiconductors, consumer products and power and industrial equipment. For
more information on Hitachi, Ltd., please visit Hitachi`s Web site at
www.hitachi.co.jp.

*At an exchange rate of 106 yen to the dollar.

About Genetics Institute
Genetics Institute is a leading biopharmaceutical company engaged in the
discovery, development and commercialization of human pharmaceuticals through
recombinant DNA and other technologies. The company has a diversified
portfolio of licensed and proprietary pharmaceutical products at various
stages of development, including treatments for anemia, hemophilia, cancer,
bone damage, inflammatory conditions and immune system disorders.

About Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. is a leader in applying population
genomics and informatics technologies to the development of personalized
medicines. Genaissance discovers genomic markers that are predictive of drug
response based on each patient`s DNA. The Company markets its technology to
the biopharmaceutical industry as a complete solution for improving drug
development, marketing and prescribing. Genaissance is located in Science
Park in New Haven, Connecticut. Additional information can be found at
www.genaissance.com.

About Integrated DNA Technologies, Inc.
Integrated DNA Technologies, Inc., an Iowa-based Biotechnology Company, is
advancing biomedical research as both a supplier of custom oligonucleotides
and a developer of innovative new biotechnology. As a leading manufacturer of
synthetic DNA/RNA, IDT provides products to over 14,000 customers worldwide.
With a comprehensive sales team, IDT has strong presence in both the academic
and corporate marketplace. IDT`s research division is committed to improving
nucleic acid synthesis technology and developing new applications for DNA and
RNA based compounds. IDT`s advanced synthesis group combines expertise in
chemistry, molecular biology, information systems and engineering to produce
and purify complex nucleic acids of all kinds. Integrated DNA Technologies is
located near major university, medical and research centers in Coralville,
Iowa with offices in the Chicago area. IDT is dedicated to being the world`s
leader in innovation and precision in nucleic acid synthesis.

About SEQUENOM, Inc.
SEQUENOM is a leader in the race to discover the medical utility of
genetic variations. The Company is translating information generated from the
map of the human genome into practical applications for improving diagnostics,
drug development and therapeutics. SEQUENOM`s distinct competitive advantage
is a comprehensive genotyping solution, including the highly accurate and
robust MassARRAY(TM) system, an automated assay development process and assay
database, the ability to analyze hundreds of samples in a single reaction and
a proven health-based concept for genetic marker validation. The Company
offers its powerful technology to customers in diagnostics, pharmacogenomics,
drug development and agricultural biotechnology, while using MassARRAY with a
novel scientific strategy for in-house programs to identify the medical
utility of SNPs. SEQUENOM is headquartered in San Diego, California with
offices in Hamburg, Germany and Boston, Massachusetts.

All statements in this press release that are not historical are forward-
looking statements within the meaning of the Securities Exchange Act of 1934,
as amended. Such forward-looking statements are subject to factors that could
cause actual results to differ materially for SEQUENOM from those projected.
Those factors include risks and uncertainties relating to technological
approaches, product development, manufacturing, market acceptance, cost and
pricing of SEQUENOM products, dependence on collaborative partners and
customers, successful performance under customer agreements, competition, the
intellectual property of others, patent protection and other risk factors
discussed from time to time in SEQUENOM`s reports and filings with the
Securities and Exchange Commission, including SEQUENOM`s Annual Report on Form
10-K for the year ended December 31, 1999 and most recent Quarterly Report on
Form 10-Q. SEQUENOM expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in SEQUENOM`s expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based.

SOURCE SEQUENOM, Inc.
-0- 09/29/2000
/CONTACT: Abigail Devine, APR, Investor Relations of SEQUENOM, Inc.,
858-350-0345, [e-mail]; or Tom Baker of Noonan/Russo
Communications, 415-677-4455, ext. 370, [e-mail], for SEQUENOM,
Inc./
/Company News On-Call: http://www.prnewswire.com/comp/124192.html or fax,
800-758-5804, ext. 124192/
/Web site: http://www.genaissance.com/
/Web site: http://www.hitachi.co.jp/
/Web site: http://www.sequenom.com/
(SQNM HIT AHP GNSC)
si

[S.Ochsenkühn]

Hallo raimundK,

es ist völlig belanglos, ob eine aktie aufgrund einer nachricht oder enttäuschten tradern einbricht oder ob sie aufgrund toller nachrichten explodiert. es ist alles nur eine frage der volatilität und somti der whal von stoppkursen und kurszielen. das chance-rendite-verhältnis bleibt gleich.

ich bin der überzeugung, dass meist erst kurse nachrichten machen und nicht umgekehrt.

und deshalb kann man auch hier mit charttechnik arbeiten. das heisst nicht, dass man fundamentale aspekte außer acht lassen soll. die technik erlaubt zumindest ein besseres timing. und im moment stimmt die technik.

grüsse
stefan ochsenkühn

[Endless]

@ S.Ochsenkühn

Hallo!!
Also nun muß ich als alter Charttechniker auch mal was sagen!! Ich finde genau wie du das man
mit Charttechnik gut arbeiten kann!! Noch muß ich dazu sagen, daß eine Menge von Tradern nach
"Charttechnik" agieren!! Ich kenne nur wenig ernsthafte und seriöse Trader die nie mit Charts arbeiten!!
Die Gefahr hierin besteht dadurch, daß bei nichtdurchbrechen wichtiger Widerstände, die Trader oft
verkaufen, siehe Situation letzter Steigflug bis 50$!!

Gruß,

Endless

[siek]

Incyte and SEQUENOM to Create World`s Largest Set
Of Validated SNP Assays For Genetic Research

PALO ALTO, Calif., and SAN DIEGO, Oct. 2 /PRNewswire/ -- Incyte Genomics,
Inc. (Nasdaq: INCY), the leading genomic information company, and SEQUENOM,
Inc. (Nasdaq: SQNM), the leading provider of SNP analysis strategies and
technology, today announced a collaboration whereby the two companies will
work together to create high-quality validated SNP assays for use in genetics
research. SNPs, single nucleotide polymorphisms, are genetic variations
between individuals and are important factors in determining disease
susceptibility and individual response to medication. Financial terms were
not disclosed.
Incyte has developed a proprietary state-of-the-art polymorphism detection
algorithm to identify SNPs from its LifeSeq(R) Gold database, the world`s most
comprehensive collection of genes. LifeSeq Gold contains over
120,000 transcribed genes, of which approximately half are proprietary to
Incyte and therefore unique. Incyte`s SNPs are particularly valuable because
they are located within genes and are likely to code for changes in gene
structure and protein sequence. SNPs that alter a gene`s function are
extraordinarily useful to researchers in understanding the molecular basis for
disease and individual response to medication.
Under the terms of the agreement, Incyte will license SNPs to SEQUENOM for
analysis and validation using SEQUENOM`s MassARRAY(TM) technology, which is
capable of analyzing hundreds of samples in a single reaction. In return,
SEQUENOM will provide Incyte with access to its MassARRAY technology and
proprietary marker validation strategies. SEQUENOM will use the validated SNP
information to develop and market 100,000 SNP assays, or tests for genetic
markers. SEQUENOM plans to make these validated SNP assays available
worldwide to genetic researchers, and will enable them to better identify the
SNPs involved in disease, and to predict associations between SNPs and
individual response to medication.
Further to the agreement, SEQUENOM will screen the SNPs against its
in-house reference human DNA bank, which contains 16,000 samples carefully
selected to represent the general population. SEQUENOM will provide allele
frequencies in four distinct ethnic groups and validate the 100,000 gene-based
SNPs for their medical utility using a proprietary and proven population
genetics approach. SEQUENOM and Incyte have agreed to jointly commercialize
the resulting intellectual property and expect to form partnership programs
for downstream product development.
Researchers using these SNP assays can access Incyte`s web site to
purchase gene sequence and annotation information and clones using LifeSeq(R)
Gene-by-Gene. This "click through" mechanism enables researchers to quickly
and easily obtain information about Incyte`s proprietary genes and to order
clones and other products for conducting further research.
"We are pleased to collaborate with SEQUENOM, a proven leader in the area
of SNP analysis, to validate pharmaceutically relevant SNPs and develop
assays," said Roy A. Whitfield, Chief Executive Officer of Incyte. "We have
focused our SNP discovery efforts on genes that are important in drug
metabolism and those that are common drug targets. By understanding the SNPs
within candidate genes in therapeutic areas and in drug metabolism response,
researchers will be able to better understand individual susceptibility to
disease, and response drugs."
"This collaboration represents the largest commercial undertaking of its
kind. Together, Incyte and SEQUENOM are pioneering the next phase of genomics
through large-scale validation of the medical utility of genetic markers,"
said Toni Schuh, Ph.D., SEQUENOM`s President and CEO. "By combining Incyte`s
high value gene-based SNPs with SEQUENOM`s proprietary SNP validation platform
and population genetics approach, Incyte and SEQUENOM will offer highly
valuable knowledge to a broad customer base and are positioned to lead the
race in generating intellectual property covering the use of genetic markers."

SEQUENOM is a post-genomics company translating information generated from
the map of the human genome into practical applications by offering a
comprehensive genotyping technology to determine the medical relevance of
genetic variations. SEQUENOM`s distinct competitive advantage is a SNP
analysis solution consisting of its highly accurate and robust MassARRAY
system, an automated assay development process and assay database, the ability
to analyze hundreds of samples in a single reaction and a proven health-based
concept for genetic marker validation. As a leader in SNP analysis, SEQUENOM
offers its powerful technology to customers in diagnostics, pharmacogenomics,
drug development and agricultural biotechnology, while using the MassARRAY
technology with a novel scientific strategy for in-house programs to identify
the medical utility of SNPs. SEQUENOM is headquartered in San Diego,
California with offices in Hamburg, Germany and Boston, Massachusetts.

Incyte Genomics, Inc. is the leading provider of an integrated platform of
genomic technologies designed to aid in the understanding of the molecular
basis of disease. Incyte develops and markets genomic databases and
partnership programs, genomic data management software, microarray-based gene
expression services, related reagents and services. These products, programs
and services assist pharmaceutical and biotechnology researchers with all
phases of drug discovery and development including gene discovery,
understanding disease pathways, identifying new disease targets and the
discovery and correlation of gene sequence variation to disease. For more
information, visit Incyte`s web site at http://www.incyte.com.

Except for the historical information contained herein, the matters set
forth in this press release, including statements as to the value of SNPs for
use in genetics research, the use of SNPs to understand the molecular basis
for disease and individual response to medication, the worldwide availability
of validated SNP assays, the joint commercialization of intellectual property,
the formation of partnership programs, and the ability to develop 100,000 SNP
assays, are forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties that may
cause actual results to differ materially, including, the utilization of SNP
assays in pharmaceutical research and development; the impact of technological
advances and competition; changes in the business plans of Incyte and
SEQUENOM; and other risks detailed from time to time in Incyte`s and
SEQUENOM`s SEC reports, including SEQUENOM`s Annual Report on Form 10-K for
the year ended December 31, 1999 and Incyte and SEQUENOM`s Quarterly Reports
on Form 10-Q for the quarter ended June 30, 2000. Incyte and SEQUENOM
disclaim any intent or obligation to update these forward-looking statements.

SOURCE SEQUENOM, Inc.; Incyte Genomics, Inc.
-0- 10/02/2000
/CONTACT: investors, Abigail Devine, APR of SEQUENOM, Inc., 858-350-0345,
[e-mail]; or John Vuko, Chief Financial Officer of Incyte
Genomics, Inc., 650-845-4106; or media, Tom Baker of Noonan/Russo
Communications, 415-677-4455, ext. 370, [e-mail], for SEQUENOM,
Inc./
/Web site: http://www.incyte.com/
/Web site: http://www.sequenom.com/
(SQNM INCY)
siek